Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Closed

Phase

Abbreviated Title

Status Notes

This study reactivated to accrual 7/15/20.

Activated

08/18/2014

Closed

01/20/2021

Participants

CTSU

Research committees

Lung Cancer

Treatment

Erlotinib

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Other Clinical Trials

SWOG Clinical Trial Number

S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Research Committee(s)

Lung Cancer

Activated

09/08/2025

Accrual

Open

Phase

SWOG Clinical Trial Number

CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)

Research Committee(s)

Lung Cancer

Activated

06/13/2025

Open

Phase

SWOG Clinical Trial Number

S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)

Research Committee(s)

Lung Cancer

Symptom Management and Survivorship

Activated

03/14/2025

Accrual

Open

Phase